Oxurion NV

Oxurion NV is a biopharmaceutical company with the slogan "Advancing Science. Enhancing Vision." Founded in 1991 and headquartered in Leuven, Belgium, Oxurion is focused on developing next-generation standard of care ophthalmic therapies. The company aims to improve and better preserve vision in patients with retinal disorders, particularly targeting diabetic macular edema (DME), the leading cause of vision loss in working-age people.

Oxurion's most promising development is THR-149, a potent plasma kallikrein inhibitor intended to become the new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. With corporate operations in Boston, MA, Oxurion is poised to revolutionize the treatment of retinal disorders, notably through the successful advancement of THR-149.

The company has attracted significant investment, with its last funding round amounting to €450.00K in post-IPO debt investment, secured on 10 April 2024. This investment was made by Atlas Special Opportunities, demonstrating investor confidence in Oxurion's potential in the biotechnology sector.

For more information about Oxurion, visit www.oxurion.com.